Clinical trials
Solid Tumor Cancer clinical trials
Below are recruiting solid tumor cancer clinical trials, each written for real people, not researchers. We’re tracking 1,444 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06506643RecruitingPhase 1/Phase 2
Study of KLS-1 for solid tumors and CLL
This trial tests a new drug called KLS-1 for people with solid tumors (like melanoma, pancreatic, or prostate cancer) or chronic lymphocytic leukemia (CLL) that is no longer responding to standard treatments. The goal is to see if KLS-1 is safe and can shrink tumors or slow the cancer.
KropyvnytskyiAges 18 years+ - NCT06500819RecruitingPhase 1
B7-H3 CAR T cells for relapsed solid tumors
This trial tests a new immune therapy using your own cells (called B7-H3 CAR T cells) to treat solid tumors that haven't responded to other treatments. It may help children and young adults with certain cancers that are hard to cure.
Palo Alto, CaliforniaAges 2–30 - NCT06400472RecruitingPhase 1
Study of drug Sofe-M for advanced solid tumors
This trial tests a new drug (Sofe-M) for people with certain advanced solid tumors, including ovarian, endometrial, cervical, lung, breast, pancreatic, or colorectal cancers. The goal is to find the best dose and see how well it works, potentially offering a new treatment option.
Scottsdale, ArizonaAges 18 years+ - NCT05807035RecruitingPhase 1
Personalized vaccine made from your tumor tissue
This Phase 1 trial tests a personalized (autologous) vaccine made from your own tumor tissue. It’s designed for people with advanced cancers who have already had at least one treatment and may still have options for getting tumor tissue for the vaccine.
Adelaide, South AustraliaAges Any age - NCT06385925RecruitingPhase 1/Phase 2
Study of TSN1611 for cancers with KRAS G12D mutation
This trial tests a new drug called TSN1611 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or stop them from growing.
Houston, TexasAges 18–75 - NCT06380309RecruitingEarly Phase 1
Study of experimental drug IDOV-SAFE for advanced digestive cancers
This trial tests an investigational drug for people with advanced digestive system cancers (like colorectal, stomach, or liver cancer) that have stopped responding to standard treatments. The goal is to see if the drug is safe and helps control the cancer.
BeijingAges 18–75 - NCT06006169RecruitingPhase 2
Study of new drugs for head and neck cancer and other solid tumors
This trial tests two new drugs, BL-B01D1 and SI-B003, alone or together, for people with head and neck squamous cell carcinoma that has come back or spread. It may also include other solid tumors. The goal is to see if these drugs can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06262919Recruiting
Monitoring safety of Tafinlar/Mekinist for BRAF-positive tumors
This study tracks the safety of the combination therapy Tafinlar and Mekinist in people with advanced or returning solid tumors that have a BRAF mutation, except for colorectal cancer. It aims to make sure the treatment is safe in the real world.
Nagakute, Aichi-kenAges 6–99 - NCT06235437RecruitingPhase 1
Testing a new drug (ASD141) for advanced solid tumors
This early-phase trial tests a new drug called ASD141 for people with advanced solid tumors that no longer respond to standard treatments. The goal is to see if it is safe and how well it works against the cancer.
TainanAges 18 years+ - NCT04954599RecruitingPhase 1/Phase 2
CP-506 for hard-to-treat cancers with DNA repair defects
This Phase 1/2 study tests CP-506 in people with advanced solid tumors that have specific DNA repair problems (homologous recombination or Fanconi anemia-related defects). It may be used alone or combined with carboplatin or an immune therapy, aiming to shrink tumors or improve control when standard options are limited.
BrusselsAges 18 years+ - NCT06131840RecruitingPhase 1
Study of SGN-CEACAM5C for advanced solid tumors
This trial tests a new drug called SGN-CEACAM5C in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein on cancer cells to try to stop them from growing.
Phoenix, ArizonaAges 18 years+ - NCT04999384RecruitingPhase 1
First-in-human dose study for advanced cancers using AN4005
This early study tests AN4005 in adults with advanced or hard-to-treat solid tumors or certain lymphomas. The goal is to find a safe dose and see how the treatment behaves in the body.
Hackensack, New JerseyAges 18 years+ - NCT06012695RecruitingPhase 1/Phase 2
Study of an oral drug for solid tumors or glioblastoma
This trial tests an oral drug called NBM-BMX for people with advanced solid tumors that have not responded to other treatments, or for people with newly diagnosed glioblastoma (a type of brain cancer). The study aims to see if the drug is safe and effective.
Kaohsiung CityAges 18 years+ - NCT05943119RecruitingPhase 2
Radiation planning after sinus surgery using dose painting
This trial tests a specialized way of planning radiation (“dose painting”) for people with cancer of the sinuses after they’ve had endoscopic surgery. It may help deliver the right radiation dose to different tumor areas while sparing nearby normal tissues.
CaenAges 18 years+ - NCT05301101Recruiting
Re-irradiation planning for tumors near previously treated organs
This study tests a more personalized way to plan “re-irradiation,” meaning giving radiation again in an area that was already treated before. It aims to better calculate organ risk to reduce harmful side effects while treating cancer.
Milwaukee, WisconsinAges 18 years+ - NCT05120596RecruitingPhase 1/Phase 2
Testing an immune-targeting drug by direct injection into tumors
This Phase 1/2 trial tests T3P, a new treatment given directly into reachable solid tumors, to see if it is safe and can help shrink tumors. It is for adults with advanced cancers when no curative treatment is available.
Pamplona, NavarreAges 18–74 - NCT04390737RecruitingPhase 1/Phase 2
Study drug HH2853 for hard-to-treat lymphoma and solid cancers
This Phase 1/2 trial tests the safety and early effectiveness of HH2853 in people whose cancer has come back or did not respond to prior treatment. It may help shrink tumors and guide future treatment for specific cancer types and genetic changes.
Phoenix, ArizonaAges 18 years+ - NCT03715933RecruitingPhase 1
Test drug INBRX-109 for advanced or metastatic solid tumors
This Phase 1 trial tests INBRX-109, a cancer-targeting drug, in people whose solid cancers are locally advanced or spread to other parts of the body. Because it’s Phase 1, the main goal is to see whether it’s safe and how well it can work for different tumor types that meet specific requirements.
Scottsdale, ArizonaAges 12–85 - NCT03093909RecruitingPhase 1
Breathing treatment with gemcitabine for lung cancer spread
This early-stage trial studies an inhaled (aerosol) form of gemcitabine to treat solid tumors that have spread to the lungs. It aims to see whether this lung-focused treatment is safe and how well it might work when standard curative options are not available.
Houston, TexasAges 12–50 - NCT01868490Enrolling by invitationPhase 1/Phase 2
Testing a patient’s immune cells for advanced solid tumors
This trial tests a modified version of your own immune cells (made from your blood) to help treat advanced cancers that are no longer responding to standard treatment. It’s designed mainly to see if the approach is safe and how well it may work for people whose disease has progressed.
Bangkoknoi, BangkokAges 8–60 - NCT07064018RecruitingPhase 1/Phase 2
SPEDOX-6 for advanced solid tumors
This trial tests a new form of the chemotherapy drug doxorubicin, called SPEDOX-6, for people with certain advanced solid tumors that haven't responded to at least two prior treatments. The drug is designed to deliver doxorubicin directly to cancer cells while possibly reducing side effects.
Orange, CaliforniaAges 18 years+ - NCT07416188RecruitingPhase 1/Phase 2
LMP744 drug for returning glioblastoma
This trial tests an experimental drug called LMP744 for people whose glioblastoma has come back. It aims to see if the drug can slow or stop tumor growth by targeting specific proteins in cancer cells.
Bethesda, MarylandAges 18–99 - NCT07015138Recruiting
Comparing two radiation approaches for prostate cancer that has spread a little
This trial is testing whether giving radiation to all spots of cancer that show up on a PSMA PET scan works better than giving radiation only to the main tumor in the prostate. It is for men whose prostate cancer has spread to a few other places (up to 10 spots).
Beijing, Beijing MunicipalityAges 18–85 - NCT04678648RecruitingPhase 1
Testing RSC-1255 in advanced cancers with RAS changes
This early study (Phase 1) tests a new drug, RSC-1255, in people with advanced or metastatic cancers that have RAS mutations. It’s mainly focused on whether the treatment can be given safely and at what dose, and to see if it may shrink tumors.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid tumor cancer?
- Yes. Clin2 currently lists 1,444 recruiting solid tumor cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid tumor cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid tumor cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.